Kansas City, Kansas 66103

  • Pulmonary Fibrosis


The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: For the idiopathic pulmonary fibrosis (IPF) Cohort - Diagnosis of IPF within 7 years - Female and males ≥ 40 years of age For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort - Evidence of progressive ILD within the 24 months before screening - Female and male ≥ 21 years of age. Exclusion Criteria: - Women of childbearing potential (WOCBP) - Active Smokers - Patients with current malignancy - History of allergy to BMS-986278 or related compounds Other protocol-defined inclusion/exclusion criteria apply



Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information
Phone: please email:
Email: Clinical.Trials@bms.com

Backup Contact:

First line of the email MUST contain NCT # and Site #.

Location Contact:

Kansas City, Kansas 66103
United States

Mark Hamblin, Site 0031
Phone: 504-905-7812

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.